Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ropivacaine hydrochloride monohydrate (LEA-103 HCl) 是钠通道阻断剂,通过可逆地抑制钠离子内流从而引起神经纤维脉冲传导阻滞。Ropivacaine HCl monohydrate 也是 K2P(双孔钾通道)TREK-1的抑制剂。在动物实验模型中,Ropivacaine HCl monohydrate 可用于神经性疼痛的缓解。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 329 | 现货 | ||
25 mg | ¥ 480 | 现货 | ||
50 mg | ¥ 672 | 现货 | ||
100 mg | ¥ 988 | 现货 | ||
200 mg | ¥ 1,460 | 现货 | ||
500 mg | ¥ 2,470 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 183 | 现货 |
产品描述 | Ropivacaine hydrochloride monohydrate (LEA-103 HCl) is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly. |
靶点活性 | TREK1 (COS-7 cell membrane):402.7 μM (IC50) |
体外活性 | Raltitrexed induces double-stranded DNA breaks in a concentration-dependent manner. In Lovo cells and LS174T cell lines containing wild-type p53, Raltitrexed increases the levels of the Bax protein up to 5-fold. In human colon cancer cells, Raltitrexed is actively absorbed into cells and is then rapidly and extensively metabolized into a series of polyglutamates, which results in the effective inhibition of thymidylate synthase. Raltitrexed is delivered to the brain very quickly and can be detected in all brain tissues within 5 minutes. In human colon cancer cells, the combination of Raltitrexed and SN-38 results in a synergistic cytotoxic effect within a range of concentrations. Raltitrexed is a specific folate-based inhibitor of thymidylate synthase. The effect on the activity of advanced rectal cancer is similar to fluorouracil (5-fluorouracil) plus leucovorin. Raltitrexed produces activity by rapid cell entry and glutamination. The glutaminated derivatives are more than 100 times more active than the parent compound. In the HCT-8 cell line, Raltitrexed results in an increase in intracellular phosphoribosyl pyrophosphate (PRPD) indicating that the cytotoxic effect of Raltitrexed in combination with 5-FU is due to increased nucleotide formation of 5-FU. Combinations of Raltitrexed and folinic acid (5FU-FA) show a combination of mode-dependent, synergistic inhibition of proliferation, which is determined by measuring the combination series. Raltitrexed combined with Vorinostat produced significant synergistic effects of cell cycle perturbation and S-phase arrest. |
别名 | Ropivacaine HCl, Ropivacaine HCl monohydrate, LEA 103, 盐酸罗哌卡因, 盐酸罗哌卡因一水合物, LEA-103 HCl |
分子量 | 328.88 |
分子式 | C17H29ClN2O2 |
CAS No. | 132112-35-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 62 mg/mL (199.44 mM)
H2O: 46 mg/mL (147.97 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 3.0406 mL | 15.2031 mL | 30.4062 mL | 76.0156 mL |
5 mM | 0.6081 mL | 3.0406 mL | 6.0812 mL | 15.2031 mL | |
10 mM | 0.3041 mL | 1.5203 mL | 3.0406 mL | 7.6016 mL | |
20 mM | 0.152 mL | 0.7602 mL | 1.5203 mL | 3.8008 mL | |
50 mM | 0.0608 mL | 0.3041 mL | 0.6081 mL | 1.5203 mL | |
100 mM | 0.0304 mL | 0.152 mL | 0.3041 mL | 0.7602 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ropivacaine hydrochloride monohydrate 132112-35-7 Membrane transporter/Ion channel Potassium Channel Sodium Channel LEA-103 hypertension Ropivacaine HCl Ropivacaine HCl monohydrate Na channels pain K(2P) neuropathic Inhibitor vasoconstrictive KcsA Ropivacaine hydrochloride Monohydrate Na+ channels Ropivacaine HCl Monohydrate potassium Ropivacaine Hydrochloride TREK-1 inhibit conduction LEA 103 Ropivacaine hydrochloride 盐酸罗哌卡因 盐酸罗哌卡因一水合物 LEA103 channel neuronal LEA-103 HCl inhibitor